Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura

Katherine J Donnithorne; T Prescott Atkinson; Claas H Hinze; Janaina B Nogueira; Shehzad A Saeed; David J Askenazi; Timothy Beukelman; Randy Q Cron

doi:10.1016/j.jpeds.2008.12.049

Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura

J Pediatr. 2009 Jul;155(1):136-9. doi: 10.1016/j.jpeds.2008.12.049.

Authors

Katherine J Donnithorne¹, T Prescott Atkinson, Claas H Hinze, Janaina B Nogueira, Shehzad A Saeed, David J Askenazi, Timothy Beukelman, Randy Q Cron

Affiliation

¹ University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.

PMID: 19559299
DOI: 10.1016/j.jpeds.2008.12.049

Abstract

To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adrenal Cortex Hormones / therapeutic use
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Child
Drug Resistance
Female
Humans
IgA Vasculitis / drug therapy*
Immunologic Factors / therapeutic use*
Male
Retrospective Studies
Rituximab
Severity of Illness Index

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab